SCHEMBL304472

SCHEMBL304472

CC1=C(CBr)C(=O)OC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6236482 0.81 TSHR (0.36)
SCHEMBL3292856 0.77 CDC25A (0.33)
SCHEMBL304729 0.75 ALDH1A1 (0.33)
SCHEMBL15268000 0.75 CDC25A (0.40)
SCHEMBL1165248 0.73 CDC25A (0.47)
SCHEMBL24925115 0.71
SCHEMBL8134293 0.71 IDO1 (0.32)
SCHEMBL138955 0.71
SCHEMBL22654547 0.71 ALOX15 (0.37)
SCHEMBL1164743 0.70 CDC25A (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4526986-A Reacting dimethyl maleic anhydride with bromotrichloro methane in the presence of actinic radiation STANDARD OIL COMPANY (INDIANA) (US) 1985-07-02 US claimed
US-20230158005-A1 Substituted Azole Dione Compounds with Antiviral Activity STEMLINE THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230158005-A1 Substituted Azole Dione Compounds with Antiviral Activity STEMLINE THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-3567035-B1 N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CANBAS CO LTD (JP) 2022-06-01 EP disclosed
EP-3567035-A1 N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Canbas Co. Ltd. (JP) 2019-11-13 EP disclosed
EP-1506218-B1 REVERSIBLE MODIFICATION OF MEMBRANE INTERACTION ARROWHEAD PHARMACEUTICALS INC (US) 2017-04-12 EP disclosed
EP-3088397-A1 COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER Canbas Co. Ltd. (JP) 2016-11-02 EP disclosed
EP-2152692-B1 COMPOUNDS WITH ANTI-CANCER ACTIVITY CANBAS CO LTD (JP) 2016-06-15 EP disclosed
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS MEIJI SEIKA KAISHA (JP) 2016-06-02 US disclosed
US-9260375-B2 Metallo-β-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2016-02-16 US disclosed
EP-1941873-A1 METALLO-BETA-LACTAMASE INHIBITOR MEIJI SEIKA KAISHA LTD. (JP) 2008-07-09 EP disclosed
US-20080090825-A1 Metallo-beta-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-17 US disclosed
US-20060122096-A1 Reversible modification of amine-containing compounds Arrowhead Madison Inc. 2006-06-08 US disclosed
US-7019113-B2 Reversible modification of membrane interaction MIRUS BIO CORPORATION (US) 2006-03-28 US disclosed
US-20050250683-A9 Reversible modification of membrane interaction Arrowhead Madison Inc. 2005-11-10 US disclosed
EP-1506218-A2 REVERSIBLE MODIFICATION OF MEMBRANE INTERACTION Mirus Corporation (US) 2005-02-16 EP disclosed
WO-2003100081-A2 BIOLOGICALLY ACTIVE MALEAMIC ACID DERIVATIVES WITH LABILE AMIDE BONDS MIRUS CORPORATION (US) 2003-12-04 WO disclosed
US-20030220264-A1 Reversible modification of membrane interaction ROZEMA DAVID B (US) 2003-11-27 US disclosed
US-4560761-A SURFACTANTS, MICROBIOCIDES, HYDRAULIC FLUIDS STANDARD OIL COMPANY (INDIANA) (US) 1985-12-24 US disclosed
US-4526986-A Reacting dimethyl maleic anhydride with bromotrichloro methane in the presence of actinic radiation STANDARD OIL COMPANY (INDIANA) (US) 1985-07-02 US disclosed